巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    NeuroBo Pharmaceuticals

    NRBO
    0.400
    0.000
    0.18%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・NeuroBo Pharmaceuticals - 延遲價格・最後更新於 15/08 9:30
    最高位
    0.425
    最低位
    0.395
    開市價
    --
    前收市價
    0.399
    成交量(千)
    7.39
    成交額(百萬)
    0.03
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    10.66
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    4.950 - 0.340
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    NeuroBo Pharmaceuticals
    證券代碼
    NRBO.US
    所屬板塊
    Biotechnology
    公司業務
    NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19. ANA001 is being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the USA. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments.
    發行量
    26593185
    公司總部
    200 Berkeley Street, Office 19th Floor
    公司網址
    https://www.neurobopharma.com
    公司電郵
    info@neurobopharma.com
    公司電話
    +1 857 702-9600
    暫無內容

    關於

    NeuroBo Pharmaceuticals(NRBO.US)所屬的行業板塊為Biotechnology。
    NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19. ANA001 is being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the USA. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments.
    詳細公司背景可參考: https://www.neurobopharma.com